Cite

HARVARD Citation

    Hamid, O. et al. (2019). Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Annals of oncology. pp. 582-588. [Online]. 
  
Back to record